Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice by Poosti, Fariba et al.
  
 University of Groningen
Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal
fibrosis after unilateral ureteral obstruction in mice
Poosti, Fariba; Bansal, Ruchi; Yazdani, Saleh; Prakash, Jai; Beljaars, Leonie; van den Born,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Poosti, F., Bansal, R., Yazdani, S., Prakash, J., Beljaars, L., van den Born, J., ... Poelstra, K. (2016).
Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after
unilateral ureteral obstruction in mice. Oncotarget, 7(34), 54240-54252.
https://doi.org/10.18632/oncotarget.11095
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget54240www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 34
Interferon gamma peptidomimetic targeted to interstitial 
myofibroblasts attenuates renal fibrosis after unilateral ureteral 
obstruction in mice
Fariba Poosti1,5, Ruchi Bansal2, Saleh Yazdani2, Jai Prakash2, Leonie Beljaars3, 
Jacob van den Born4, Martin H. de Borst4, Harry van Goor1, Jan-Luuk Hillebrands1,* 
and Klaas Poelstra3,*
1 Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, University of 
Groningen, Groningen, The Netherlands
2 Department of Biomaterials Science and Technology, Division of Targeted Therapeutics, MIRA Institute, University of 
Twente, Enschede, The Netherlands
3 Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Groningen, The Netherlands
4 Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, 
Groningen, The Netherlands
5 Department of Microbiology and Immunology, Laboratory of Molecular Immunology, Rega Institute, KU Leuven, Belgium
* Share senior authorship
Correspondence to: Jan-Luuk Hillebrands, email: j.l.hillebrands@umcg.nl
Keywords: drug targeting, fibrosis, interferon gamma, kidney, myofibroblast, Pathology Section
Received: March 07, 2016 Accepted: June 20, 2016 Published: August 05, 2016
AbstrAct
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is 
lacking. Interferon-γ is a pro-inflammatory cytokine with anti-fibrotic properties. 
Clinical use of interferon-γ is hampered due to inflammation-mediated systemic side 
effects. We used an interferon-γ peptidomimetic (mimγ) lacking the extracellular 
IFNγReceptor recognition domain, and coupled it to the PDGFβR-recognizing peptide 
BiPPB. Here we tested the efficacy of mimγ-BiPPB (referred to as “Fibroferon”) 
targeted to PDGFβR-overexpressing interstitial myofibroblasts to attenuate renal 
fibrosis without inducing inflammation-mediated side effects in the mouse unilateral 
ureter obstruction model.
Unilateral ureter obstruction induced renal fibrosis characterized by significantly 
increased α-SMA, TGFβ1, fibronectin, and collagens I and III protein and/or mRNA 
expression. Fibroferon treatment significantly reduced expression of these fibrotic 
markers. Compared to full-length IFNγ, anti-fibrotic effects of Fibroferon were 
more pronounced. Unilateral ureter obstruction-induced lymphangiogenesis was 
significantly reduced by Fibroferon but not full-length IFNγ. In contrast to full-length 
IFNγ, Fibroferon did not induce IFNγ-related side-effects as evidenced by preserved 
low-level brain MHC II expression (similar to vehicle), lowered plasma triglyceride 
levels, and improved weight gain after unilateral ureter obstruction.
In conclusion, compared to full-length IFNγ, the IFNγ-peptidomimetic Fibroferon 
targeted to PDGFβR-overexpressing myofibroblasts attenuates renal fibrosis in the 
absence of IFNγ-mediated adverse effects.
                   Research Paper: Pathology
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INtrODUctION
Patients with chronic kidney disease (CKD) are at 
increased risk of progression to end-stage renal disease 
(ESRD). Virtually all forms of CKD are characterized 
by significant amounts of renal fibrosis [1, 2]. Renal 
interstitial fibrosis is the final common process observed 
in various kidney diseases that leads to renal failure, 
and is associated with tubular atrophy and dilation, 
interstitial matrix deposition, accumulation of interstitial 
fibroblasts, and inflammatory cell infiltration [3]. There is 
still no effective therapy to halt renal fibrogenesis, and to 
prevent progression to ESRD of which the latter requires 
renal replacement therapy eventually [4]. Among the 
characteristic changes in the kidney during development of 
fibrosis, interstitial extracellular matrix (ECM) deposition 
is the key step. Interstitial fibroblasts are the predominant 
source of ECM constituents. Therefore, dampening of 
interstitial fibroblast activation and subsequent prevention 
of differentiation into ECM-producing myofibroblasts, is 
an attractive approach to attenuate development of renal 
interstitial fibrosis [5-7]. 
Interferon-γ (IFNγ) is a cytokine primarily produced 
by T cells and natural killer (NK) cells. It is a pleiotropic 
cytokine with anti-viral, anti-bacterial, anti-tumor, pro-
inflammatory but also anti-fibrotic activities [8]. Because 
of the latter, IFNγ is a potential effective biological to treat 
or prevent renal fibrosis [9-12]. However, its potential 
therapeutic value in fibrosis has been limited so far due 
to the systemic side effects (because of widespread IFNγ 
receptor [IFNγR] expression) and rapid renal clearance 
[13-15]. In order to overcome these problems as well as to 
attain high concentrations in the target cells, cell-specific 
targeting via receptor-mediated uptake of biologicals is an 
attractive approach. 
Activated fibroblasts in fibrotic tissue are 
characterized by increased platelet-derived growth factor 
receptor-beta (PDGFβR) expression [16, 17], and this 
prompted us to use the PDGFβR for receptor-mediated 
uptake of biologicals. To do so, pegylated full length IFNγ 
was conjugated to PDGFβR-recognizing peptide (PPB) 
[18] and by using this conjugate (i.e. PPB-PEG-IFNγ) 
we were able to demonstrate anti-fibrotic effects in the 
CCl
4
-induced liver fibrosis mouse model [19] and anti-
tumorigenic effects by targeting stromal cells in the B16 
melanoma tumor mouse model [20]. Recently we used the 
same targeting approach as proof of concept in the mouse 
unilateral ureteral obstruction (UUO) model of renal 
fibrosis in which anti-fibrotic effects of the PPB-PEG-
IFNγ conjugate were demonstrated [12]. Despite the anti-
fibrotic effects of PPB-PEG-IFNγ, systemic side effects 
were mildly reduced but remained still present compared 
to full length IFNγ as evidenced by increased brain MHC 
class II expression. This side effect was most likely due 
to binding of the full length IFNγ to the ubiquitously 
expressed IFNγR. 
To overcome the problem of IFNγR-mediated 
systemic side effects we recently designed a new IFNγ-
based biological which lacks the amino-terminal IFNγR-
binding sequence [21, 22]. This IFNγ-peptidomimetic 
(mimγ) was conjugated to the bicyclic platelet-derived 
growth factor receptor-beta recognizing peptide (BiPPB) 
for targeting to PDGFβR-expressing cells (schematically 
depicted in Figure 1a). The mimγ-BiPPB was recently 
renamed “Fibroferon” [23]. Here we tested the hypothesis 
that compared to the previously tested non-targeted 
full-length IFNγ [12], specific delivery of Fibroferon 
to PDGFβR-overexpressing interstitial myofibroblasts 
attenuates renal fibrosis and reduces inflammation-
mediated side-effects in the mouse UUO model.
rEsULts
PDGFβR expression is increased on interstitial 
myofibroblasts in UUO mouse kidneys
We first analyzed PDGFβR expression in mouse 
sham and fibrotic (UUO) kidneys. Confirming our 
previous data, fibrosis in UUO is characterized by 
increased interstitial PDGFβR expression as revealed 
by increased mRNA expression (Figure 2a) and protein 
expression (based on immunohistochemistry) (Figure 2b). 
w
Fibroferon reduces renal fibroblast activation
In order to determine whether Fibroferon reduces 
renal fibroblast activation in vivo, α-SMA expression was 
determined at both mRNA and protein level. As shown 
in Figure 3a, UUO (receiving subsequent treatment 
with vehicle) resulted in increased (p < 0.001) α-SMA 
mRNA expression compared to sham controls. α-SMA 
mRNA expression after treatment with Fibroferon and 
non-targeted full length IFNγ was significantly lower 
compared with vehicle-treated UUO mice (p < 0.05 vs. 
vehicle), and similar to sham-operated (no UUO) mice. 
Immunohistochemistry confirmed increased α-SMA 
expression in UUO kidneys (vehicle treatment, p < 0.01 
vs. sham, Figure 3b,c). Representative photomicrographs 
of α-SMA staining are shown in Figure 3b. Quantitative 
analysis revealed significantly reduced α-SMA protein 
expression after Fibroferon treatment when compared to 
vehicle treatment (p < 0.05 vs. vehicle, Figure 3c). 
Since TGFβ1 is known to induce α-SMA expression 
in fibroblasts [24] we also analyzed TGFβ1 mRNA 
expression in sham and UUO kidneys. UUO (vehicle) 
significantly increased renal TGFβ1 expression (p < 0.01 
vs. sham), which was not prevented by Fibroferon or IFNγ 
treatment (Figure 3d).
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Figure 1: Schematic representation of the structure of the targeted IFNγ peptidomimetic Fibroferon (mimγ-BiPPB) 
and its binding to PDGFRβ-expressing myofibroblasts (a), and the in vivo treatment regimen in the mouse unilateral 
ureter obstruction (UUO) model (b). 
Figure 2: UUO increases PDGFßR expression on mRNA (a) and protein (b) expression level. a. Relative gene expression 
of PDGFßR in UUO (vehicle-treated) and sham-operated control kidneys at day 7 post surgery. **p < 0.01 vs. sham. Bars represent mean ± 
SEM of 5-6 mice per group. b. Representative photomicrographs (200x) of kidney sections from sham-operated and vehicle-treated UUO 
mice stained for PDGFßR. 
Oncotarget54243www.impactjournals.com/oncotarget
Fibroferon reduces extracellular matrix (ECM) 
deposition in UUO kidneys
Next we analyzed the effects of Fibroferon on ECM 
constituent expression using immunohistochemistry. 
Clear differences in protein expression were observed 
when comparing the different treatment groups (Figure 
4). In UUO (vehicle) significantly increased protein 
expression levels for interstitial fibronectin (Figure 4a), 
collagen I (Figure 4b), and collagen III (Figure 4c) were 
observed 7 days post-UUO compared to sham-operated 
mice (all p < 0.01 vs. sham). Compared to vehicle, only 
treatment with Fibroferon resulted in significantly reduced 
fibronectin (Figure 4a, p ≤ 0.05), collagen I (Figure 4b, p 
< 0.01), and collagen III (Figure 4c, p ≤ 0.05) expression. 
Protein expression in non-targeted full length IFNγ did not 
statistically differ from vehicle-treated mice. Compared 
with non-targeted full length IFNγ, these data indicate that 
Fibroferon is more effective in reducing ECM constituent 
expression.
Effects of Fibroferon on renal inflammation in 
UUO
IFNγ exerts systemic pro-inflammatory effects but 
possibly also local intra-renal inflammatory responses. To 
analyze the latter, we determined whether treatment with 
non-targeted full length IFNγ and Fibroferon resulted in 
different intra-renal inflammatory responses as determined 
by qPCR analyses, and CD3+ T cell infiltration. As shown 
in Suppl. Figure 1, compared to sham-operated mice, 
UUO (with subsequent vehicle treatment) resulted in 
significantly increased MCP-1 (a), TNF-α (b), IL-1β (c) 
and IL-6 (d) mRNA expressions (all p < 0.01 vs. sham). 
Although Fibroferon tended to reduce, and reciprocally 
non-targeted full length IFNγ tended to increase pro-
inflammatory cytokine production (vs. vehicle), no 
statistically significant differences were observed. 
UUO (vehicle) significantly increased renal MHC 
class II expression that was reduced after Fibroferon 
treatment when compared with non-targeted full length 
IFNγ (Suppl. Figure 1e). This might be explained by 
increased IFNγ-induced macrophage activation rather than 
macrophage influx (Suppl. Figure 1f). Additionally, UUO 
resulted in increased CD3+ T cell influx as determined 
by immunohistochemistry (p < 0.01 vs. sham) that was 
reduced by mimγ-BiPPB (58% reduction) and non-
targeted full length IFNγ-treated mice (42% reduction) 
(Suppl. Figure 1g). 
Fibroferon reduces lymphangiogenesis
New lymph vessel formation (lymphangiogenesis) 
has been shown in different renal disease models, 
including UUO [25]. This led us to hypothesize that UUO-
induced renal lymphangiogenesis might be attenuated 
following Fibroferon treatment. Compared to sham, 
UUO (vehicle treatment) indeed increased numbers of 
podoplanin+-lymph capillaries (p < 0.01 vs. sham) which 
were significantly lower in Fibroferon-treated (p ≤ 0.05 
vs. vehicle), but not in non-targeted full length IFNγ-
treated mice (Figure 5a). Depending on the time after 
UUO induction, both angiogenesis (increase in capillary 
density) and capillary rarefaction has been described [26]. 
We analyzed the effect of Fibroferon and non-targeted 
full length IFNγ on peritubular capillary density. As 
shown in Figure 5b, UUO (vehicle) was associated with 
significantly increased numbers of CD31+ peritubular 
capillaries (p < 0.01 vs. sham), which was not reduced 
by Fibroferon. Photomicrographs shown  in Figure 5a and 
5b display representative photos of podoplanin+ lymph 
capillaries and CD31+ peritubular capillaries in UUO 
(vehicle, Fibroferon, and non-targeted full length IFNγ 
treatment) and sham kidneys, respectively. 
Fibroferon treatment is accompanied by less 
systemic side effects
To assess whether treatment with Fibroferon reduces 
systemic side effects compared with non-targeted full 
length IFNγ, brain MHC class II mRNA expression (as 
a measure of IFNγ-induced microglia activation) and 
plasma triglyceride levels (as a measure of IFNγ-induced 
lypolysis in adipose tissue) were determined. As shown in 
Figure 6a, in line with our previous observations [12, 19, 
21] treatment with non-targeted full length IFNγ caused 
significant (p < 0.01) up-regulation of brain MHC class II 
expression. In contrast, upon Fibroferon treatment brain 
MHC class II expression was similar to vehicle-treatment. 
Compared with non-targeted full length IFNγ, Fibroferon 
treatment significantly reduced plasma triglyceride levels 
(p < 0.05, Figure 6b). Compared with vehicle, plasma 
triglyceride levels were not significantly increased after 
non-targeted full length IFNγ treatment (not shown), 
which might be explained by the fact that we used non-
pegylated full length IFNγ. Finally, we determined weight 
loss and recovery after induction of UUO in the various 
treatment groups. As shown in Figure 6c, mice receiving 
wFibroferon displayed less weight loss and accelerated 
weight gain after UUO when compared to non-targeted 
full length IFNγ treated mice, which might be explained 
either by attenuating the renal damage and/or by reducing 
side effects in mice receiving Fibroferon. 
DIscUssION
In this study we demonstrate pronounced anti-
fibrotic effects of targeted IFNγ peptidomimetic to 
PDGFβR-expressing cells without identifiable systemic 
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Figure 3: Fibroferon reduces α-SMA expression in mouse UUO kidneys. a. Relative gene expression of α-SMA in fibrotic 
UUO and sham-operated control kidneys at day 7 post surgery. b. Representative photomicrographs of α-SMA stained kidney sections 
of sham-operated and UUO mice treated with vehicle (PBS), Fibroferon or (non-targeted full length) IFNγ (200x). Scale bar = 120 μm. 
c. Computerized quantitative analysis of α-SMA protein expression in UUO and sham-operated kidneys. d. Relative gene expression of 
TGFβ1 in UUO and sham-operated kidneys. Quantitative data of UUO are expressed relative to sham. *p ≤ 0.05, **p < 0.01, ***p < 0.001. 
Bars represent mean ± SEM of 5-6 mice per group.
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Figure 4: Fibroferon reduces extracellular matrix deposition (fibronectin, collagen I, and collagen III) in mouse UUO 
kidneys. Representative photomicrographs (200X) and computerized quantitative analysis of a. fibronectin, b. collagen I, and c. collagen 
III protein expression in UUO and sham-operated kidneys. Scale bar = 120 μm. Quantitative data of UUO are expressed relative to sham. 
*p ≤ 0.05, **p < 0.01. Bars represent mean ± SEM of 5-6 mice per group. 
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side effects in the UUO mouse model of renal fibrosis. 
This strategy of targeting a chimeric anti-fibrotic 
biological to PDGFβR provides new opportunities for 
the treatment of renal fibrosis as well as other conditions 
associated with enhanced PDGFβR expression such as 
cancer and vascular remodeling.
Renal fibrosis is the result of tissue injury and 
remodeling and is a common hallmark and cause of ESRD 
[27]. Myofibroblast activation and proliferation play a 
fundamental role in fibrosis progression [28]. Recent 
progress in understanding the mechanisms underlying 
the pathogenesis of fibrosis has led to the expectation 
that various cytokines such as IFNγ could be potentially 
useful therapeutics to halt or even prevent fibrosis [29]. 
However, the major obstacle in IFNγ-based therapy is 
the manifestation of clinical side effects, which has led 
to abortion of clinical trials or restricted diverse clinical 
use of IFNγ [14, 15, 30, 31]. These adverse effects 
often preclude administration of anticipated therapeutic 
effective dose, leading to lack of efficacy in patients. 
In line with this, we previously showed that systemic 
delivery of non-targeted full length IFNγ in mice results 
in leukocyte and endothelial cell activation, flu-like 
symptoms, neurotropic effects, hyperlipidemia, elevated 
TNF-α and IL-6, inflammation of the central nervous 
system, and elevated triglyceride levels [19], effects most 
likely mediated through binding to the widely expressed 
IFNγR. To overcome this hurdle, cell-specific delivery 
of IFNγ provides a new approach to improve its efficacy 
and to ameliorate potential systemic side effects. To 
prevent canonical IFNγ signaling, we used mimγ, which 
lacks the INFγR- binding domain. Mimγ targeted to liver 
stellate cells was recently shown to exert anti-fibrotic 
activity in vivo [21, 22]. Here we tested the anti-fibrotic 
effects of mimγ targeted to PDGFβR-expressing cells in a 
model of renal fibrosis. Mimγ was directed to interstitial 
myofibroblasts using a bicyclic PDGFβR-recognizing 
peptide (Bi-PPB). The mimγ-BiPPB was recently renamed 
Fibroferon [23].
Interstitial myofibroblasts are characterized by 
increased expression of PDGFβR in the human and 
mouse fibrotic kidney [12]. Bi-PPB is a bi-cyclic peptide 
that binds to the dimeric PDGFβR and may thus be 
used to deliver the mimγ peptide to the target cells. To 
determine its anti-fibrotic effects, we first examined 
α-SMA expression both at the mRNA and protein levels 
since increased α-SMA levels indicate renal myofibroblast 
activation, the hallmark of fibrogenesis. We indeed 
observed a clear inhibitory effect of mimγ-BiPPB on 
myofibroblast activation (i.e. reduced α-SMA expression). 
ECM composition is significantly altered and expanded 
during fibrogenesis, which can severely compromise 
resident cell function (e.g. tubular epithelium) [5, 32]. 
We therefore analyzed expression of the most prominent 
ECM components fibronectin, and collagens I and III. 
Again, a clear pharmacological effect of Fibroferon was 
noted, and compared to non-targeted full length IFNγ 
the efficacy of Fibroferon in reducing ECM deposition 
was significantly higher, illustrating the potency of our 
cell-specific targeting strategy. Of note, although mRNA 
expression levels of fibronectin and collagens I & III were 
lower in Fibroferon-treated mice compared with vehicle-
treated mice, these differences were not significant (data 
not shown). These data suggest that the protective effects 
of Fibroferon are (partly) mediated by enhanced fibrolysis 
as we demonstrated previously using another interferon-γ 
based conjugate in a model of liver fibrosis [33]. TGFß1 is 
a pro-fibrotic protein which instigates fibroblast activation 
and transformation into myofibroblasts, resulting in 
collagen synthesis and ECM contraction [24]. However, 
we did not observe altered TGFß1 expression after IFNγ 
or Fibroferon treatment.
Inflammation commonly precedes and accompanies 
fibrosis [34]. There is evidence for a direct role of T cells 
in the pathogenesis of renal interstitial fibrosis which can 
be explained through different mechanisms [35, 36]: (1) 
direct effects on fibroblast activation and ECM deposition, 
(2) indirect effects on fibroblasts via induction of a pro-
fibrotic phenotype of infiltrating macrophages resulting 
in fibroblast activation through profibrotic cytokines 
and growth factors (e.g. PDGF, CTGF, TGFß1), and (3) 
indirect effects on fibroblasts via tubular epithelial cell 
activation and subsequent production of cytokines and 
growth factors that act on fibroblasts. We indeed observed 
an almost two-fold reduction in the number of infiltrating 
T cells after mimγ-BiPPB treatment, possibly mediated 
via reduced expression of T cell chemoattractants that are 
shown to be produced by myofibroblasts [37, 38]. 
In the setting of renal fibrosis, injured renal cells and 
inflammatory cells secrete mediators and growth factors 
that promote angiogenesis and/or lymphangiogenesis [37-
41]. Since anti-lymphangiogenic effects of IFNγ have 
been reported [42], we analyzed the potential inhibitory 
effect of Fibroferon on lymphangiogenesis. Renal 
lymphangiogenesis in UUO kidneys was significantly 
reduced following Fibroferon treatment, which was not 
observed after treatment with non-targeted full length 
IFNγ. Angiogenesis was also shown to occur during the 
progression of fibrosis in UUO [43], which was confirmed 
in our study. A reduction, though non-significant, was 
observed in the percentage surface area of CD31+ 
peritubular capillaries following Fibroferon treatment. 
Reduced lymphangiogenesis and angiogenesis most likely 
reflect indirect effects secondary to the direct anti-fibrotic 
effects of Fibroferon on myofibroblasts.
Recently we reported on the anti-fibrotic effects 
of full length IFNγ targeted to PDGFβR-expressing 
myofibroblasts in UUO mice [12]. When comparing the 
anti-fibrotic effects of targeted full length IFNγ [12] and 
Fibroferon, the attenuating effects on αSMA and ECM 
constituents are comparable. However, clear differences 
were observed in favor of Fibroferon with respect to 
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Figure 5: Fibroferon reduces UUO-induced lymphangiogenesis. Representative photomicrographs and quantitative analysis 
of a. the numbers of podoplanin+ lymphatic capillaries and b. the numbers of CD31+ peritubular capillaries 7 days post-surgery. Arrows 
indicate podoplanin+ lymphatic capillaries in sham kidney. Scale bar = 50 μm. Quantitative data of UUO are expressed relative to sham. *p 
< 0.05,**p < 0.01. Bars represent mean ± SEM of 5-6 mice per group. 
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CNS and renal inflammation. Compared with targeted 
full length IFNγ [12], brain MHC class II expression was 
79% reduced upon Fibroferon treatment. Similarly, renal 
F4/80 and MHC class II expression were significantly 
reduced with 33% and 53%, respectively. We used MHC 
class II expression as a marker of macrophage activation. 
Macrophages are the main target cells for native INFγ. For 
anti-fibrotic therapies, generalized macrophage activation 
is an off-target effect leading to serious adverse effects, 
and the brain is an off-target organ for renal diseases. 
Our data indicate that Fibroferon lacks this off-target 
effect, in contrast to targeted full length IFNγ, which 
can be explained by the lack of Fibroferon binding to the 
extracellular domain of IFNγR. A potential weakness of 
current study is that we did not include data demonstrating 
a direct comparison between targeted full length IFNγ 
(PPB-PEG-IFNγ) and Fibroferon. However, we recently 
published on the anti-fibrotic effects of PPB-PEG-IFNγ 
[12], and, compared with the vehicle control group, the 
beneficial anti-fibrotic effects of Fibroferon are similar. 
Figure 6: Fibroferon prevents IFNγ-related systemic side effects and improve weight gain after surgery. a. mRNA 
expression of brain MHC class II in UUO mice treated with vehicle (PBS), Fibroferon or non-targeted full length IFNγ (7 days post-
surgery). Data of UUO groups are expressed relative to sham. **p < 0.01, Student’s t-test. Bars represent mean ± SEM of 3 mice per group. 
b. Plasma triglyceride levels in UUO mice treated with vehicle (PBS), Fibroferon or non-targeted full length IFNγ, 7 days post-surgery. *p < 
0.05. Bars represent mean ± SEM of 5-6 mice per group. c. Weight loss and recovery in UUO mice treated with vehicle (PBS), Fibroferon, 
and (non-targeted full length) IFNγ. ****p < 0.001. Change in weight expressed as mean ± SD of 6 mice per group/time point.
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 The mechanism by which Fibroferon exerts its 
protective effects is not yet fully elucidated. We previously 
demonstrated mimγ playing a direct role in the activation 
and nuclear translocation of the transcription factor 
STAT1α via the nuclear signaling sequence (NLS) present 
in the C-terminal region of IFNγ. This region is able to 
modulate IFNγ-responsive genes through activation of 
the JAK/STAT pathway [21]. Mimγ does not recognize 
the extracellular domain of IFNγR but rather binds to the 
cytoplasmic domain of the receptor chain 1 (IFNγR1), and 
thereby initiates cellular signaling [44-49]. Binding of Bi-
PPB to the PDGFβR has been demonstrated in previous 
studies 19, 20. We propose that mimγ-BiPPB binds to the 
PDGFβR and following internalization, the construct is 
able to interact with the intracellular part of IFNγR1 and 
initiates phosphorylation of STAT1 thereby eliciting IFNγ-
related biological effects. Fibroferon just has the IFNγ 
signaling moiety and is only biologically active once it 
is internalized. This premise needs further study though. 
In conclusion, in this study we demonstrate the 
benefits of (targeted) Fibroferon over non-targeted full 
length IFNγ with respect to its anti-fibrotic effects and 
the development of off-target systemic side effects. We 
demonstrate a proof-of-concept strategy for the use of 
targeted IFNγ-based biologicals to reduce renal fibrosis 
by removing the extracellular receptor recognition 
sequence and directing it to myofibroblasts. The small 
size and increased stability of Fibroferon compared to the 
full length targeted IFNγ will provide better therapeutic 
benefits and more possibilities for subcutaneous or 
muscular administration. In addition, based on these and 
our previous data we believe that Fibroferon offers high 
specificity and low toxicity with full agonistic activity, 
therefore has highly favorable characteristics for the 
prolonged administration. This strategy is one of the first 
examples of re-direction of a cytokine to the kidney by 
creating a chimeric peptide. Our data warrant further 
exploration of the precise underlying mechanism and 
mode of action of Fibroferon as well as of the possibility 
to use Fibroferon to target fibrosis in a clinical setting.
MATERIALS AND METHODS
Experimental animals and surgical procedures
Male C57Bl/6 mice (9-12 wks; 28-30 g) were 
obtained from Harlan (Zeist, the Netherlands). Animals 
were housed in cages with free access to food and 
water. During the operation the abdomen was opened 
by a midline incision under general anesthesia (2% 
isoflurane/O
2
). All mice were subjected to unilateral 
ureteral obstruction (UUO) by a double-ligation (using 
6-0 silk suture) of the left ureter proximal to the kidney. 
Right kidneys were used as sham controls and were 
manipulated but not ligated. After surgery, mice were i.v. 
injected (penile vein) at days 2, 4 and 6 after surgery (see 
Figure 1b) with either 1) UUO, vehicle (saline), 2) UUO, 
Fibroferon (mimγ-BiPPB, 5 µg/mouse/injection), 3) UUO, 
non-targeted full-length IFNγ (5 µg/mouse/injection). 
Total follow-up time was 7 days during which mice were 
weighed daily. Group size was n = 6/group/time point. 
The experimental animal studies have been approved by 
the local Institutional Review Board of the University 
of Groningen (DEC 6066B) and adhered to the national 
guidelines for the care and use of laboratory animals. 
Synthesis of Fibroferon conjugate
All the chemical reactions were performed in low 
protein binding tubes (LoBind tubes, Eppendorf, Hamburg, 
Germany). Bicyclic PDGFβR-recognizing peptide 
(CSRNLIDC-GGGDGG-CSRNLIDC with C”C disulfide 
bonds, BiPPB, 2223 Da) [18] and peptidomimetic IFNγ 
(mimIFNγ, 4689 Da) modified with S-acetyl thioacetate 
were custom-prepared by Genosphere (Paris, France). 
To synthesize the construct, BiPPB (0.112 µmol) was 
reacted with 0.337 µmol of Maleimide-PEG-succinimidyl 
carboxy methyl ester (Mal-PEG-SCM, 2 KDa, Creative 
PEGworks, Winston-Salem, NC) for 3 h. Thereafter, 
excess of Mal-PEG-SCM was blocked with lysine (0.337 
µmol) for 1 h. Subsequently, the prepared BiPPB-PEG-
Mal was reacted overnight with mimIFNγ-ATA in the 
presence of deacetylating reagent (0.1M hydroxylamine, 
25mM EDTA in PBS pH 7.2). The prepared mimIFNγ-
PEG-BiPPB (mimγ-BiPPB [Fibroferon]) conjugate (8.9 
KDa) was extensively dialyzed against PBS using 7 kDa 
dialysis membrane (Thermo Scientific, Rockford, IL). 
Antibodies
For immunohistochemistry the following primary 
antibodies were used: anti-alpha smooth muscle actin 
(α-SMA, clone ASM-1, Progen Biotechnik, Heidelberg, 
Germany); anti-fibronectin (ab6584, Abcam, Cambridge, 
UK); anti-CD3 (A0452, Dako, Glostrup, Denmark); 
anti-podoplanin (clone RTD4E10, Acris antibodies, 
Inc, Herford, Germany.); anti-PDGFβR (#3169, Cell 
signaling, Danvers, USA), anti-CD31 (clone SZ31, 
Dianova GmbH, Germany); anti-type I collagen (s1310-
01, SouthernBiotech, USA) and anti-type III collagen 
(s1330-01, SouthernBiotech, USA). 
Immunohistochemistry
Immunohistochemistry for α-SMA, fibronectin, 
type III collagen, CD31, podoplanin, and CD3 was 
performed on 2 µm paraffin sections. Sections were 
deparaffinized in xylene and rehydrated in graded alcohol 
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series and distilled water. Antigen retrieval was achieved 
by overnight incubation at 80ºC in 0.1 M Tris/HCl buffer 
(pH 9.0) for fibronectin and type III collagen staining, 
and treatment in the microwave for 15 min at 300W 
with 10 mM citrate buffer (pH 6:0) for podoplanin and 
CD31 staining. No antigen retrieval was performed for 
α-SMA staining. Type I collagen and PDGFβR staining 
was performed on 4 µm acetone-fixed frozen sections. 





 (in PBS) for 30 min. Primary antibody binding 
was detected by sequential incubations with horseradish 
peroxidase (HRP)-labeled appropriate secondary and 
tertiary antibodies (all obtained from DAKO, Glostrup, 
Denmark). Peroxidase activity was visualized using 3, 
3’-diaminobenzidine tetrahydrochloride (DAB, DAKO, 
Glostrup, Denmark) as chromogen (10 min. incubation). 
Sections were counterstained with hematoxylin for 1 min 
and mounted with Kaiser‘s glycerin gelatin.
Quantification of immunostaining
The sections were scanned using a NanoZoomer 
HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). 
The extent of cortico-interstitial α-SMA, fibronectin, type 
I and III collagens, and CD3 expression was measured 
as numbers of positive pixels, and the numbers of 
podoplanin-positive vessel-like structures were counted 
in 30 cortical areas using Aperio ImageScope software 
(version 9.1.772.1570, Aperio Technologies Inc, Vista, 
CA, USA) at 200x magnification. For CD31 staining, 10 
cortical areas at 400x magnification were selected, and 
the percentage of CD31 positive area was measured using 
ImageJ 1.46r (Rasband, W.S., U.S. National Institutes of 
Health). 
Quantitative real-time PCR
Total RNA from kidney tissues was extracted 
using RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. The RNA 
concentrations were measured on a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific, USA). Single-
stranded cDNA was synthesized using Superscript II and 
random hexamer primers (Invitrogen, Carlsbad, CA) in a 
volume of 20 μl. cDNA’s were diluted to a concentration 
of 2 ng/μl and 2.5 μl/reaction (5 ng) was used for qRT-
PCR analysis. PCR reactions were performed in a 
10 μl reaction volume containing 1 x qPCR master 
mix (EUrogentec, Liege, Belgium), 1x Taqman Gene 
Expression Assay mix (Applied Biosystems, Forster City, 
CA). The primer reference numbers were as follows: 
Ywhaz: Mm03950126_s1, α-SMA/Acta2: Mm01546133_
m1, MHC-II/CD74: Mm00658576_m1, and PDGFβR: 
Mm00435546_m1. qRT-PCR reactions were performed 
on a ABI7900HT thermal cycler (Biosystems, Forster 
City, CA). Relative gene expression was calculated using 
the 2-ΔCt method with Ywhaz (tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein ζ) as 
housekeeping gene. Data are expressed as fold-change 
compared to sham-operated kidneys.
Plasma triglyceride measurements
Whole blood was collected into commercially 
available EDTA-coated tubes (Item No: 450474, Greiner 
Bio-One, GmbH, Austria). The tubes were kept on ice 
during processing. Cells were removed from plasma by 
centrifugation for 10 minutes at 1000-2000 x g using a 
refrigerated centrifuge. Triglyceride levels were measured 
on a Vitalab Selectra-E chemistry workstation (Vital 
Scientific BV, Spankeren, The Netherlands).
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software Inc, La Jolla, CA). 
Differences between multiple groups were calculated 
using the non-parametric one-way ANOVA (Kruskal-
Wallis test) with Dunn’s Multiple Comparison Test post-
test. Comparison of two groups was performed using the 
Mann Whitney test (or Student’s t-test where indicated). 
Comparison of weight loss and recovery in the various 
groups was performed using Repeated Measures ANOVA 
with Bonferroni post-test. p ≤ 0.05 was considered 
statistically significant. Data are expressed as mean ± 
standard error of the mean (or mean ± standard deviation 
where indicated). 
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